Press releases
- Charles River Laboratories Announces First-Quarter 2024 Results
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- Charles River to Perform Plasmid Production for Ship of Theseus
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
- Charles River Laboratories Publishes 2023 Corporate Citizenship Report
More ▼
Key statistics
As of last trade Charles River Laboratories International Inc (RV6:FRA) traded at 204.80, -18.67% below its 52-week high of 251.80, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 204.80 |
---|---|
High | 204.80 |
Low | 204.80 |
Bid | 204.40 |
Offer | 205.70 |
Previous close | 204.00 |
Average volume | 16.11 |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 26.17 |
Market cap | 11.49bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of May 21 2024 07:01 BST.
More ▼